Home | Publications | Therapeutic place holder
place holder place holder

Therapeutic

Contemporary Targeted Therapies in Rheumatology


Publication Date   August 2007
Publisher   Informa Healthcare
Product Type   Book
Pages   720
ISBN Number   978-1-84184-484-8
Product Code   IFH069
Ask a question about this product?

Price £95.00

approximately: $168 | €120

Summary


Review for the previous volume from Annals of Internal Medicine (140:2, 2004): "This is a quality textbook that highlights the important advances that have enhanced, or are likely to enhance, the treatment of many serious chronic inflammatory and autoimmune diseases.

Each of the authors was selected on the basis of their published contributions to an exciting literature" Targeted Therapies in Rheumatology established itself as an excellent reference for all those needing to know about the clinical implications of new drugs and developments for patients suffering from rheumatoid arthritis. This volume takes up the further developments that have occurred in several of the drug therapies covered in the first volume, as well as looking at the latest areas of promising research.

Content


  • Section I - Cells and Cell Surface Receptors
    • 1. T Cells - Overview - Update
    • 2. Co-Stimulation: A
    • Cd80/86 - Cd28 , Ctla-4
    • 3. Regulatory T Cells
    • 4. B Cell Antigen Receptor Signalling and Autoimmunity
    • 5. Plasma Cells
    • 6. Targeting B Lymphocyte Stimulator (Blys) in Immune-Based Rheumatic Diseases: A Therapeutic Promise Waiting to Be Fulfilled
    • 7. Macrophages - Overview - Update
    • 8. Dendritic Cells
    • 9. Toll-like Receptors
    • 10. Cadherins
    • 11. Complement and Pregnancy Loss
    • 12. Osteoclasts
    • 13. Cell Contact Dependence of Inflammatory Events
  • Section Ii - Cytokines, Chemokines and Other Effector Molecules
    • 14. Update on Tnfa
    • 15. Targeting Interleukin-1 in Rheumatic Diseases - Update
    • 16. Update on Il-6
    • 17. Update on Il-15
    • 18. Update on Il-18
    • 19. Update on Opg/Anti- Rankl
    • 20. Interleukin-32
    • 21. Interleukin-13
    • 22. Il-17: A New Target in Arthritis
    • 23. Interleukin 21
    • 24. The Interferons
    • 25. Update - Inflammatory, Angiogenic and Homeostatis Chemokines and Their Receptors
  • Section Iii - Transcription Factors and Signalling Molecules
    • 26. Update on Nfkb
    • 27. Update on Jak/Stats
    • 28. Suppressor of Cytokine Signalling (Socs) Proteins as Therapeutic Targets in Rheumatoid Arthritis
    • 29. The Various Pathways of Cytokine Signalling - Wnt Signalling
    • 30. Nfat
    • 31. Signalling in Osteoclasts and Osteoblasts
  • Section Iv - Inflammatory Mediators
    • 32. Inflammatory Mediators: Update on Cyclooxygenases and Pg Synthases
  • Section V - Matrix Molecules
    • 33. Update on Matrix Metalloproteinases
    • 34. The Adam Family of Mmps
  • Section Vi - Targeted Therapies in Human and Experimental Rheumatic Diseases
    • 35. Update on Proinflammatory Cytokine Blockade in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    • 36. Update on Targeted Therapy in Psoriatic Arthritis
    • 37. Update on Ankylosing Spondylitis
    • 38. Early Arthritis - Update
    • 39. Juvenile Arthritis - Update
    • 40. Update - Systemic Lupus Erythmatosus
    • 41. Vasculitis - Update
    • 42. Myositis - Update
    • 43. Tnf-Blockade in Orphan Rheumatic Diseases
    • 44. Overview of The Safety of Tnf Inhibitors
    • 45. Anti-Cd20
    • 46. Ctla-4ig
    • 47. Anti-Il6r
    • 48. Anti-Cd3 Antibody - An History of Successful Immune Interventions
    • 49. Alefacept
    • 50. Anti-Vla-4
    • 51. Anti-Il-15
    • 52. Clinical Prospects of Mapk Inhibitors
    • 53. Clinical Prospects of Nfkappab Inhibitors to Advance Targeted Therapies in Rheumatology